L-BLP25 vaccine plus letrozole for breast cancer: Is translation possible?

OncoImmunology

Volumn 1, Issue 8, 2012, Pages 1422-1424

  DeGregorio, Michael ^a   Wurz, Gregory T ^a   Gutierrez, Audrey ^a   Wolf, Michael ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Merck Serono GmbH   (Germany)

Author keywords

Breast cancer; L BLP25; Letrozole; MMT model; Tamoxifen

Indexed keywords

ANASTROZOLE; CISPLATIN; CYCLOPHOSPHAMIDE; DACLIZUMAB; DOXORUBICIN; EMEPEPIMUT S; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA CHAIN; GLYCOGEN SYNTHASE KINASE 3BETA; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; I KAPPA B KINASE BETA; I KAPPA B KINASE GAMMA; IDARUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LETROZOLE; MITOXANTRONE; MUCIN 1; OXALIPLATIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE PHOSPHODIESTERASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE PHOSPHODIESTERASE 1; PROTEIN KINASE C DELTA; PROTEIN KINASE ZAP 70; PROTEIN P53; PROTEIN SHC; TAMOXIFEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER HORMONE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER STAGING; CELL SURVIVAL; DRUG MECHANISM; HUMAN; LOW DRUG DOSE; LYMPHOCYTE SUBPOPULATION; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSLATIONAL RESEARCH; TUMOR MICROENVIRONMENT;

EID: 84875366067     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21129     Document Type: Note

References (10)

1. Mehta NR, Wurz GT, Burich RA, Greenberg BE, Griffey S, Gutierrez A, et al. L-BLP25 vaccine plus letrozole induces a TH1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice. Clin Cancer Res 2012; 18:2861-71.
2. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 2003; 163:2113-26.
3. Carson DD. The cytoplasmic tail of MUC1: a very busy place. Sci Signal 2008; 1:pe35.
4. Behjati S, Frank MH. The effects of tamoxifen on immunity. Curr Med Chem 2009; 16:3076-80.
5. Wang JX, Zhang QY, Jin S, Feng MY, Kang XM, Zhao S, et al. Immoderate inhibition of estrogen by anastrozole enhances the severity of experimental polyarthritis. Exp Gerontol 2009; 44:398-405.
6. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005; 105:2862-8.
7. Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell DJ Jr., et al. CD25 blockade depletes and selectively reporgrams regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med 2012; 4:134.
8. Collins JL, Kao MS. The anticancer drug, cisplatin, increases the naturally occurring cell-mediated lysis of tumor cells. Cancer Immunol Immunother 1989; 29:17-22.
9. Yamaue H, Tanimura H, Noguchi K, Iwahashi M, Tsunoda T, Tani M, et al. Cisplatin treatment renders tumor cells more susceptible to attack by lymphokineactivated killer cells. J Clin Lab Immunol 1991; 35:165-70.
10. Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012; 104:599-613.